Publication | Closed Access

IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC

Progression-free SurvivalSquamous NsclcMedicinePharmacologyImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyLung CancerNab-paclitaxel Vs Carboplatin